Patient engagement is not new in pharma. For years, companies have invested in patient advocacy, advisory boards, support programs, and storytelling initiatives designed to bring the patient voice closer to decision-making. These continue to be vital elements of patient engagement. 

What is changing now is that patient insight is about more than engagement – it is fast becoming a critical form of evidence used to inform regulatory, reimbursement, and access decisions across healthcare. 

Regulators are evolving quickly. The FDA’s patient-focused drug development guidance, growing reliance on real-world evidence, and increasing emphasis on outcomes that matter to patients are reshaping expectations around what constitutes meaningful evidence. In Europe, new HTA frameworks are increasing scrutiny on comparative effectiveness, quality of life, and lived experience. 

At the same time, healthcare stakeholders want more than traditional clinical trial evidence alone. Payers want proof of real-world value. Providers want evidence that patients can adhere to and benefit from therapies in real-world settings. Patients themselves increasingly expect to be active participants in the development process. 

Taken together, these shifts are redefining the role of patient insight in healthcare decision-making. 

For much of the past decade, patient engagement often sat adjacent to core development and commercial strategy. Stories created empathy and awareness, but they were rarely treated as decision-grade inputs. Today, that is rapidly changing. 

Organizations across the healthcare ecosystem are increasingly expected to operationalize patient insight into evidence that regulators, payers, providers, and biopharmaceutical leaders can act on. The ability to demonstrate lived experience, treatment burden, quality of life, and real-world outcomes is becoming essential to how therapies are evaluated, differentiated, reimbursed, accessed, and adopted. 

In other words, patient evidence is becoming table stakes for access and healthcare decision-making. 

The organizations that succeed in this next era of biopharmaceutical development will be those that move beyond viewing patient engagement as a communications exercise and instead embed patient evidence across the product lifecycle, combining clinical, real-world, and lived-experience data into a more complete understanding of therapeutic impact. 

The future of pharma will not be defined solely by scientific innovation, but by which organizations most effectively translate patient experience into evidence that drives better decisions, stronger outcomes, broader access, and greater trust. 

All of this is why I’m particularly excited to share that AppliedPX, a leading patient engagement and patient insights firm, has joined Reservoir. We’re excited to welcome Elisabeth and Joe to our team.  

AppliedPX is helping accelerate the shift toward decision-grade patient evidence by translating lived experience into structured, actionable insights that can inform clinical development, market access, engagement strategy, and commercialization. Through Reservoir’s work across policy, communications, and market enablement, patient evidence becomes a critical tool for shaping how therapies are understood, valued, accessed, and adopted. 

Together, we look forward to helping ensure that the patient is not only represented in the conversation but embedded in the evidence that drives decisions from innovation through access. 

For more information, check out our announcement.